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Inherited retinal degenerations, including retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA), aﬀect 1 in 4000
individuals in the general population. A majority of the genes which are mutated in these conditions are expressed in either
photoreceptors or the retinal pigment epithelium (RPE). There is considerable variation in the clinical severity of these conditions;
the most severe being autosomal recessive LCA, a heterogeneous retinal degenerative disease and the commonest cause of
congenital blindness in children. Here, we discuss all the potential treatments that are now available for retinal degeneration. A
number of therapeutic avenues are being explored based on our knowledge of the pathophysiology of retinal degeneration derived
fromresearchonanimalmodels,including:genetherapy,antiapoptosisagents,neurotrophicfactors,anddietarysupplementation.
Technological advances in retinal implant devices continue to provide the promise of vision for patients with end-stage disease.
1.RetinitisPigmentosa
Retinitis pigmentosa (RP) describes a heterogeneous group
of inherited retinal dystrophies characterized by progressive
photoreceptor cell degeneration that aﬀects approximately
1 in 4000 in a general population [1]. The genetics of
RP is varied; nonsyndromic cases may be inherited as an
autosomal dominant (30%), autosomal recessive (20%), X-
linked recessive (15%), or sporadic/simplex traits (30%),
a n d5 %m a yb ee a r l y - o n s e ta n dg r o u p e da sp a r to fL e b e r
congenital amaurosis [2]. Rarer forms also exist: X-linked
dominant, mitochondrial, and digenic (due to mutations in
two diﬀerent genes). While RP is a disease usually limited
to the eye, it may occur as part of a syndrome; as examples,
Usher syndrome and Bardet-Biedl syndrome. Approximately
20%–30% of patients with RP have an associated nonocular
diseaseandwouldbeclassiﬁedashavingsyndromicRP.Alist
of nonsyndromic and syndromic RP is maintained through
RetNet (http://www.sph.uth.tmc.edu/retnet/). A majority of
the genes associated with RP are expressed in either the pho-
toreceptorsortheretinalpigmentepithelium(RPE).Thereis
considerable variation in the severity of these conditions; the
most severe being recessively inherited conditions generally
resulting in loss of function of an important protein in a
pathway.
RP is characterized by progressive degeneration of the
retina usually starting in the midperiphery of the fundus
and advancing towards the macula and fovea. The most
common form of RP is a rod-cone dystrophy in which night
blindnessistheﬁrstsymptom,followedbyprogressivelossof
peripheral visual ﬁeld. Classic clinical ﬁndings include: bone
spicule pigmentation or pigment clumping, retinal arteriolar
narrowing, waxy pallor of the optic nerve, epiretinal mem-
brane formation, atrophy of the RPE and choriocapillaris
(starting at the midperiphery of the retina with preservation
of the RPE in the macula until late in the disease), posterior
subcapsular cataract, epiretinal membrane formation, and
cystoid macular edema (CME) [1].
PotentiallyimportantﬁndingscanbeobtainedfromERG
recordings. The term rod-cone dystrophy, commonly used
to describe RP, denotes the predominant system aﬀected by
retinal degeneration (rod versus cone) and is reﬂected by
the rod-driven responses of the ERG being more severely
aﬀected than cone-driven responses. Early in the disease, the
rod ERG amplitude is aﬀected more than the cones; and with
progression, the rod and cone responses are “extinguished”.2 Journal of Ophthalmology
Visual ﬁeld testing often reveals a mid-peripheral ring
scotoma which enlarges peripherally and centrally as the
disease progresses.
In the majority of cases, RP is an isolated disorder, but
infrequently is associated with other systemic conditions for
which treatment strategies have been implicated; for exam-
ple, abetalipoproteinemia (MIM no. 200100) and Refsum
disease (MIM no. 266500). Adult-onset Refsum disease is an
autosomal recessive disorder of lipid metabolism caused by
a deﬁciency of phytanic acid hydroxylase. Clinically, patients
present in early childhood with cardiomyopathy, ichthyosis,
neurologic diseases (polyneuritis, spinocerebellar ataxia,
hearing loss, and loss of smell), and odd-shaped red blood
cells. The ocular ﬁndings include: nystagmus, strabismus,
pupillaryabnormalities,cataract,andRP.Treatmentrequires
dietary restriction of plant foods and milk which are sources
of phytanic acid.
Abetalipoproteinemia or Bassen-Kornzweig syndrome
(MIM no. 200100) is an autosomal recessive disorder in
which there is abnormal absorption of fat and fat-soluble
vitamins, A, D, E, and K. The signs and symptoms of abetal-
ipoproteinemia appear in the ﬁrst few months of life with
failure to thrive, steatorrhea and acanthocytosis. Vitamin A
deﬁciency may result and lead to retinal degeneration that is
treatable with vitamin supplementation.
Leber congenital amaurosis (LCA), (MIM no. 204000)
was ﬁrst described in 1869 by Theodore Leber as a congenital
form of RP [3, 4] .L C Ai sa na u t o s o m a lr e c e s s i v ed i s o r d e r
that is genetically and clinically heterogeneous. LCA is the
most severe inherited retinopathy and the most common
cause of congenital blindness in children, accounting for
10%–18% of cases [3, 5, 6]. LCA has several phenotypes;
symptoms or fundus ﬁndings within the ﬁrst year of life
may suggest a particular genotype [3, 7, 8]. Clinical features
include: nyctalopia, photoaversion, eye poking (oculodigital
sign), nystagmus, hyperopia, an abnormal fundus, and an
abnormal ERG [3, 7].
At least 14 genes are associated with LCA and involve
various pathways including: retinal development (CRB1 and
CRX), phototransduction, (GUCY2D and AIPL1), vitamin A
metabolism (RPE65, LRAT,a n dRDH12), protein transport
(TULP1, RPGRIP1,a n dCEP290), and RPE phagocytosis
(MERTK)[ 8]. Together LCA and juvenile-onset retinal
degeneration constitute 70% of cases of severe retinal
degenerationorretinaldystrophy.Severalofthesegeneshave
also been implicated in nonsyndromic or syndromic retinal
diseases such as RP and Joubert syndrome, respectively.
CEP290 (15%), GUCY2D (12%), and CRB1 (10%) are the
most frequently genes found to be mutated in cases of
LCA.
2. Gene Therapy
Gene therapy holds promise for a wide variety of inherited
human disease. To date, ocular gene therapy (OGT) has been
tried with success in mice, dogs, and now in some humans.
OGT requires genetic modiﬁcation of mutant ocular cells to
produce a therapeutic eﬀect. Retinal diseases are excellent
targets of OGT as in many cases, the genetic etiology is
understood, and there is access to the photoreceptors or the
retinal pigment epithelium (RPE) by subretinal injection.
In addition, both transgenic and knockout animal models
are available that provide preclinical evidence of safety and
eﬃcacy. OGT requires ﬁrst identifying the genetic cause of
the RP, and then genotyping patients for mutations in that
gene prior to enrolment in gene therapy trials.
Gene therapy strategies diﬀer greatly depending on the
inheritance of the disease or more accurately the type of
mutation targeted. Some forms of RP are due to loss-
of-function mutations (usually autosomal and X-linked
recessive). For OGT to be eﬀective, the therapy must replace
the missing or insuﬃcient gene product. For example, Tan
and colleagues used adenoviral vectors to transduce two
mouse models of RP/LCA due to aryl hydrocarbon receptor
protein-like 1 (Aipl1) deﬁciency (hypomorphic mutant) and
absence (null mutant), establishing the potential of gene
replacement therapy in the human condition [9].
Human OGT is most advanced for the form of LCA
associated with mutations in RPE65 [10–14]. Preliminary
studies in the Briard dog, a naturally occurring model of
LCA (rpe65-/-),helpedmakeclinicaltrialspossible.Asimilar
degenerationisseenintheSwedish-Briard/Briard-beagledue
to a 4-base pair deletion in the rpe65 gene [15]. The initial
studyofOGTindogswasdoneintheUSA[5,6,16]andlater
in France [17]. Surgical delivery of recombinant adenovirus
associated vectors (AAV) carrying the wild type rpe65 cDNA
into the subretinal space of three aﬀected dogs demonstrated
eﬃcacy as measured by improved ERG responses. The dogs’
vision improved in the treated eye and has been stable after
ﬁ v ey e a r s .M o r et h a nﬁ f t yd o g sh a v es i n c eb e e nt e s t e df o r
their response to OGT. Successful gene therapy has also been
demonstrated in mice with mutations in the rpe65 gene
[16]. The treatment rescued photoreceptors and also retinal
function as measured by the ERG.
The results of separate human trials in the USA, UK,
and Italy enrolling patients with mutations in the RPE65
gene have been reported with encouraging results [11–14].
Bainbridge et al. [11] and Maguire et al. [14]ﬁ r s td e s c r i b e d
separate clinical trials investigating the short-term safety and
preliminaryeﬃcacyofOGTforLCAinhumans.Bothgroups
initially presented short-term data (12 and 5 months, resp.)
on three LCA patients enrolled in trials of recombinant AAV
delivery of the human RPE65 gene into the subretinal space.
In both studies, patients had severe vision loss documented
by visual acuity testing and the ERG. Both studies showed
some improvement in navigational testing in at least one
patient. This outcome measure has yet to be accepted as a
measure of functional visual improvement.
Bainbridge and colleagues studied their patients with
microperimetry (which measured retinal sensitivity at pre-
cise locations in light-adapted conditions) and observed an
improvement aftergenetherapy in one patient [11].Maguire
et al. observed visual ﬁeld improvement using Goldmann
perimetry and decreased nystagmus after treatment in all
their three patients [14] whereas Bainbridge et al. only noted
improvement in the dark-adapted perimetry of one patient
[11]. Bainbridge et al. [11] showed no change in patients’Journal of Ophthalmology 3
visual acuity whereas Maguire et al. [14]r e c o r d e dag a i n
in visual acuity in all three patients in their study. These
outcomes must be replicated with additional subjects and
patients’functionassessedlongterm.Further,ifsafetycanbe
demonstrated,patientswithbettervisualfunctionatbaseline
should be included in future trials.
Maguire et al. employed the pupillary light reﬂex as an
objective measure of retinal function and found improve-
ment in each of the treated eyes [14]. The pupillary light
reﬂex is a consensual response; a light stimulus to either eye
will normally cause both pupils to contract. Fundamentally,
it is a measure of the amount of signal input from the
photoreceptors, interneurons, and ganglion cells, conveyed
through an aﬀerent arc to the brain, with the output
drivingbilateralpupilconstriction.Thepupillaryresponseof
patientswithLCAissigniﬁcantlydiminished,consistentwith
decreasedphotoreceptorinputtotheaﬀerentarcofthereﬂex
[14, 18–20]. In a report of a total of 12 patients (age 8–44)
who had undergone OGT for LCA, all had an improvement
in the pupillary response, with the greatest eﬀect seen in
children [21].
Optical coherence tomography (OCT) allows a non-
invasive measure of photoreceptor layer thickness in the
central retina of LCA patients [22]. The topography of the
photoreceptorlayerbasedonOCTscans,withsuperimposed
retinal landmarks, should be available to the retinal surgeon
to guide the subretinal injection of AAV gene vectors. The
response to treatment may also be measured with OCT.
Photoreceptor loss in the fovea and extrafoveal retina has
been shown to be prominent, even in the youngest LCA
patient studied. As disease severity in LCA has a broad
spectrum, detailed retinal imaging and mapping with OCT
should be conducted in all candidates for LCA-RPE 65
clinical trials, independent of age [23].
The ERG responses were extremely low or undetectable
in patients in both studies at baseline and remained
unchanged after treatment. Whether the improvements in
retinal function are reproducible and persistent in subjects
remain as questions along with whether retinal degeneration
is delayed or averted. Systemic or ocular complications may
yet be encountered as additional patients are treated with
higher doses of vector and followed for longer periods.
Alternates to OGT for the treatment of LCA are
also being pursued; for example, oral administration of a
reti-noid, QLT091001 (NCT00765427, NCT01014052, see:
http://www.clinicaltrials.gov/). Preliminary results, presen-
tedattheAssociationforResearchonVisioninOphthalmol-
ogy meeting in May, 2010, suggested improved function in
three LCA patients with RPE65 and LRAT mutations.
For autosomal dominant RP, caused by gain-of-function
mutations, eﬀective therapy must either prevent the mutant
protein from being produced or counter the expression of
the protein. Ribozymes catalyze enzymatic reactions that
break down RNA [24, 25]. Conceptually, it would, therefore,
be possible to use ribozymes to treat autosomal dominant
RP by blocking the gene product from the mutant allele,
thereby halting or slowing the progression of the disease.
In 1998, Drenser et al. [26] showed that ribozyme could
be used to decrease the amount of mutant rhodopsin
messenger RNA. Later, the same group used recombinant
AAV to transduce photoreceptor cells of rhodopsin mutant
(pro23his) transgenic rats with ribozyme and an opsin
promoter, demonstrating that ribozyme could slow pho-
toreceptor degeneration. They showed that treatment was
eﬀective at age 1 month and 1.5 months when 40%–45% of
photoreceptors would have normally degenerated [27, 28].
The pro23his mutation in rhodopsin represents a change
from proline to histidine at position 23 and is the most
common rhodopsin mutation in humans. By targeting only
the mutant RNA sequence, ribozyme therapy is mutation-
dependent and therefore limited in its application. Auto-
somal dominant RP is genetically heterogeneous; 25% of
cases are caused by diﬀerent mutations in rhodopsin and the
remaining cases are not linked to rhodopsin. Unique gene
therapies with a large number of ribozymes would have to be
developed for each of these disorders.
RNA interference (RNAi) is mutation-independent and
a powerful method for posttranslational gene silencing. In
mammalian systems, small interfering RNAs (siRNAs) are
introduced directly into the cell or processed in the cell
from translated short hairpin RNA (shRNA) [29] and then
assembled into an RNA-induced silencing complex known
as RISC. RISC allows the antisense strand to form a duplex
with the target messenger RNA which is then degraded by an
enzyme, and then rendered inactive. Compared to ribozyme
therapy, RNAi is at least as potent, less dependent on
RNA secondary structure and does not require a particular
sequence motif. RNAi has been used to identify genes that
promote apoptosis or oxidative damage in retinal cells and
could provide new avenues for treatment of photoreceptor
degenerations [30, 31].
3.Retinal Implants
The treatment of RP patients with severe visual loss
using either epiretinal or subretinal implants was reviewed
recently by Margalit et al. [32]. Humayun et al. reported
direct retinal stimulation using epiretinal implants in RP
patients [33]. Using a 16-electrode array, patients saw
spots of light that were usually colored (yellow/blue/yellow-
green)andthedirectionofmovement (http://www.artiﬁcial-
retina.energy.gov/ and Second Sight Medical Products, Inc.
Sylmar, CA). Resolution in this model is believed to be up
to 1.8 degrees of visual ﬁeld. At the 2009 annual meeting of
the Association for Research on Vision in Ophthalmology,
the Artiﬁcial Retina Project released an update on the Argus
II, a 60-electrode retinal prosthesis. As of March 31, 2009,
21 people with RP had been implanted with the device; this
number continues to rise as more subjects are enrolled in
a Phase II, three year clinical trial. Although the Argus II
prosthesisconsistsofanarrayof60electrodesattachedtothe
retina, the project aims to increase the number of electrodes
beyond 200.
Caspi et al. [34] used a 16 electrode retinal prosthesis in
a totally blind subject with RP. The implant was controlled
wirelessly by an external computer and head mounted
video camera. Spatial vision was assessed by measuring the4 Journal of Ophthalmology
subject’s response to direct stimulation patterns and by com-
paring the ability of the subject to identify the orientation
of gratings with the system on and oﬀ. Results showed
that synchronized stimulation of diﬀerent retinal locations
could produce spatial vision long term with an acuity level
determined by the distance between the electrodes.
Yanai et al. [35] assessed visual task performance in
three subjects blinded by RP. An epiretinal prosthesis was
implanted in the eye with worse vision and the input
was wirelessly controlled by a computer or head-worn
video camera. Subjects scored better in 8 of 9 computer-
controlled experiments. This study, although small in size,
suggested that a low-resolution, epiretinal prosthesis could
provide visual information to perform simple tasks that were
impossible with only light perception vision.
Subretinal electrodes have been attempted in animal
models and the results indicate that cortical activity can
be induced [36, 37]. Similar experiments have since been
initiated in humans [38]. The long-term eﬀect of the
implants has not been assessed, nor has the eﬀect of the
electrodes placed between the neuroretina and the retinal
pigment epithelium on retinal metabolic function.
4. Neurotrophic Factors
Several neuorotrophic factors have been shown to pro-
tect photoreceptors from degeneration, including ciliary
neurotrophic factor (CNTF). In diﬀerent animal mod-
els of retinal degeneration, CNTF was shown to delay
photoreceptor degeneration [27, 39–42]. A thicker outer
nuclear layer was observed in treated animals, reﬂecting
preservation of the photoreceptors and anatomical rescue.
Electrophysiologicalrecordingsperformedtoevaluateretinal
function demonstrated an improvement in the scotopic
and photopic responses recorded from CNTF-treated eyes
compared to untreated eyes [39, 41]. Glial cell line-derived
neurotrophic factor (GDNF) has also been shown to have
an e u r o p r o t e c t i v ee ﬀect on degenerating photoreceptors by
slowing down the degeneration of rods while preserving
visual function [42].
While neuroprotective factors may oﬀer promising
results in the treatment of RP in animal models, eﬀec-
tive treatment strategies need to be developed for clinical
delivery. Direct intravitreal or subretinal neurotrophic factor
injections have been performed in animal models with
therapeutic eﬀect; [43] however, an implantable device
allows for long term delivery avoiding repeated injections
with the risk of mechanical or infectious complications.
Ex vivo gene therapy is a promising approach whereby
genetically engineered and encapsulated human retinal pig-
ment epithelial cells are implanted into the vitreous in a
device [44]. A Phase I safety trial of the delivery of CNTF
through encapsulated cell therapy was completed on patients
with RP (one of which had choroideremia) without serious
adverse event and some suggestion of improvement in visual
acuity. A Phase II trial are currently underway and designed
to show eﬃcacy in treating atrophic macular degeneration
and RP [45].
5. Retinal Transplantation
Retinaltransplantationplacessheetsofdevelopingretinaand
retinal pigment epithelial cells into the subretinal space [46].
Whereas adult transplants have been performed in humans
with RP and age-related macular degeneration (AMD);
[47] the transplants have not caused harm but there is no
evidence that the cells of the transplanted tissue mingle
with or develop synaptic connections. Radtke and his group
reported eﬃcacy and safety in implanting fetal retina with
accompanying RPE in AMD and RP patients with vision of
20/200. Seven of the ten patients showed improved visual
acuity, corroborating results in animal models of retinal
degeneration [48].
An alternate approach may be the transplantation of
photoreceptor precursors. MacLaren and colleagues demon-
strated that the timing of the harvest of the donor cells
must be at the correct stage of rod morphogenesis, when
they have exited the cell cycle and are in the ﬁrst stages
towards becoming mature photoreceptors [49]. If the cells
were isolated just a couple of days too early or too late,
they would not integrate into the retina. When successful,
the treated eye showed an improved pupillary light response
suggesting that the transplanted cells were responsive to light
andhadintegratedintotheretinalcircuitryconnectingtothe
central nervous system.
Lamba et al. incubated human embryonic stem cells
in a complex cocktail that coaxed cells into becoming
photoreceptor progenitors [50]. These progenitors, like the
in vivo derived progenitors described by MacLaren et al.,
were able to integrate into degenerated mouse retinas [49].
It may be possible to prepare unlimited numbers of pro-
genitor cells that are suitable for transplantation regardless
of whether donor progenitor cells are isolated from adult
tissue or from embryonic stem cells. How can one ensure
as u ﬃcient number of stem cells that are available for an
eﬀectivegraft?MacLarenet al.showedthatit isnot necessary
to integrate each precursor cell with each secondary neuron
to achieve a therapeutic eﬀect [49] .A l s o ,i tm a yn o tb e
necessary to treat the entire retina; treatment of the macula
alone may suﬃce.
6. Stem Cells
Enzmann and colleagues have reviewed the use of stem
cells, their plasticity, their ability to give rise to specialized
cells, and their capacity for self-renewal [51]. Lund and
coworkers have derived RPE cells that are critical to the
health of photoreceptors from human embryonic stem
cells [52]. The RPE cells were then transplanted into rats
with retinal degenerative disease. The investigators reported
that the improvement in vision of treated rats was 100%
over untreated controls. Although the RPE cells were not
suﬃciently developed to completely replace the damaged
RPE, they were able to rescue vision by the long-term
production of growth factors beneﬁcial to the health of the
retina. Lund and his collaborators are proceeding to produce
entirely functional RPE and photoreceptors from stem cells
to replace and repair degenerated retinas in humans.Journal of Ophthalmology 5
7. Light Protection
Clinical evidence and data from animal studies suggest that
somepigmentaryretinopathiesareparticularlysusceptibleto
light damage [53]. Patients with RP are advised to wear dark
glasses outdoors. The use of amber spectacles should block
ultraviolet rays and visible wavelengths up to about 527nm.
Outdoors, it is ideal to use spectacles that block ultraviolet
rays and light up to approximately 550nm to ﬁlter blue
light.
8. Vitamin Therapy
Vitamin A may protect the photoreceptors by trophic and
antioxidant eﬀects. Long-term (5 to 15 year) vitamin A
supplementation in doses of 15,000IU per day slowed down
the loss of ERG amplitudes [54]. Vitamin E at 4,000IU
had an adverse eﬀect [54]. Clinicians continue to debate
the conclusions of these studies [55]. There is no consensus
about the utility of vitamin A treatment. Vitamin A should
not be given to patients with RP caused by mutations
in the ABCA4 gene. In another study, RP patients were
given docosahexaenoic acid (DHA) supplementation at
1200mg/day in addition to vitamin A [56]. This study
showed that the disease course was initially slowed by the
addition of DHA; however, the beneﬁcial eﬀect did not
last beyond two years. Berson and colleagues have reported
on the beneﬁts to RP patients of a diet rich in omega-3
fatty acids [57]. RP patients taking vitamin A palmitate,
but not DHA capsules, beneﬁted from an omega-3 rich diet
(equivalent to eating salmon, tuna, mackerel, herring, or
sardines, once to two times a week). Recently, Berson and
colleagues reported on patients taking Vitamin A randomly
assigned to either lutein supplementation (12mg/da) or
placebo over a four year period [58]. Lutein appeared to slow
the decline in the mean rate of sensitivity loss as measured by
the Humphrey visual ﬁeld 60-test. An accompanying article
in the same journal discussed carefully the merits of all these
studies [59].
A study of the potential beneﬁt of DHA in patients
with X-linked RP is ongoing [60]. Patients between the
ages of 8 and 32 who have X-linked RP are enrolled in
a four year, Phase II, clinical trial studying the eﬀect of
nutritional supplementation with DHA. DHA is a compo-
nent of cell membranes throughout the body, and most
highly concentrated in the retina and the brain where it
plays a role in phototransduction and synaptic transmission
[47].
9. DrugDelivery
Agroupofinternationalexpertsindrugdeliveryarestudying
the treatment of retinal degenerative diseases by long-term,
sustained drug delivery through the sclera [61–64]. They
are also investigating a range of delivery devices such as
microneedles, collagen gels, and the use of an electric ﬁeld.
Better methods of drug delivery could be crucial for future
therapies to save or restore sight.
10. Macular Edema
Cystoid macular edema (CME), which occurs frequently
in RP patients, is often chronic and may not improve
with carbonic anhydrase inhibitors [65, 66]. A trial of
therapy over two months may instituted, and if eﬀective,
should be continued indeﬁnitely; if no response is seen with
treatment, it should be discontinued. Care must be taken
when considering long-term acetazolamide as it has been
shown to depress the ERG responses in mice [67]. In a small
trial of 20 treated RP patients and 20 matched untreated RP
controls, intravitreal triamcinolone (4mg) did not result in a
statistically signiﬁcant improvement in best corrected visual
acuity [68].
11. Conclusion
Therapies are becoming available to restore vision or stop
the progressive loss of visual function caused by pigmen-
tary retinopathies. The psychological boost to researchers,
patients, and families from the results of LCA gene therapy
trials is very evident. Therapeutic strategies are being
designed and applied to slow down the degenerative process,
to treat ocular complications, and to help with the social
and psychological impact of blindness resulting from RP.
Approaches to therapy for RP now include: gene ther-
apy, neurotrophic growth factors, anti-apoptotic agents,
ribozyme therapy, RNAi, retinal transplantation, dietary
supplementation, retinal prostheses, and stem cell therapy.
We hope that, in the future, discoveries from the laboratory
will be brought into the clinical setting.
12.Method ofLiteratureSearch
References for this paper were identiﬁed through a compre-
hensive English-language literature search of the electronic
Medline database (1993–2009), using the Medline search
service. Search of other databases did not add to the search
of Medline. The following key words were used alone or
in combination: retinitis pigmentosa, rod-cone dystrophy,
RP,RNAi,neurotrophicgrowthfactors,encapsulatedcellular
therapy, ciliary neurotrophic factor, anti-apoptosis, genes,
bionic eye, precursor photoreceptor transplantation, optical
aids, cystoid macular edema, Leber congenital amaurosis,
retinal cell transplantation, precursor photoreceptors, treat-
ment, and Vitamin A.
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